FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136540711> ?p ?o ?g. }

• W3136540711 abstract "Aim: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are equally recommended as the first-line antiviral treatments for chronic hepatitis B (CHB) at present. We aimed to compare the long-term efficacy and safety between ETV and TDF therapy in CHB patients who had not received nucleoside analog treatment. Method: In this single-center retrospective study, 414 patients who received ETV (290 patients) or TDF (124 patients) therapy at our center from January 2017 to May 2019 were included. To reduce the imbalance of baseline variables, propensity score matching (PSM) was employed to yield 124 pairs of patients at a ratio of 1:1 based on the treatment regimen. Result: After PSM, the cumulative rate of patients who achieved complete virological response (CVR) was not different by drug therapy at each inspection time (1, 3, 6, 12, 18, and 24 months). Subgroup analysis on HBeAg status and level of HBV DNA demonstrated that evolution of proportion of achieving CVR was not significantly different between groups. Despite the insignificant incidence of HBsAg seroclearance in either group, patients in TDF group achieved higher on-treatment HBsAg decline at each inspection time (1, 3, 6, 9, 12, 18, and 24 months), 0.39, 0.51, 0.61, 0.64, 0.68, 0.76, and 0.91 log IU/mL, respectively; while the corresponding reduction were 0.27, 0.37, 0.40, 0.45, 0.48, 0.55, and 0.66 log IU/mL in ETV group ( p &lt; 0.05). In subgroup analysis, we found that the significant difference still existed in patients with high baseline HBsAg level (&gt;3 log IU/mL). Additionally, the proportion of patients who achieved on-treatment HBsAg decline &gt;1 log IU/mL in TDF and ETV group was 33.3 and 17.1% ( p &lt; 0.01) at the 12th month, 44.4 and 29.5% ( p = 0.03) at the 24th month, respectively. Mean increase in serum creatinine from baseline was 0.10 and 0.08 mg/dL in TDF and ETV group ( p = 0.11), with no patient experienced acute kidney injury. Conclusions: TDF has higher potency in reducing HBsAg than ETV in this study. Considering the effect still existed in patients with high HBsAg level (&gt;3 log IU/mL), TDF might be a superior therapeutic regimen combining with its relatively safety." @default.
• W3136540711 created "2021-03-29" @default.
• W3136540711 creator A5003240832 @default.
• W3136540711 creator A5010353663 @default.
• W3136540711 creator A5011302477 @default.
• W3136540711 creator A5018159361 @default.
• W3136540711 creator A5019709596 @default.
• W3136540711 creator A5081134218 @default.
• W3136540711 date "2021-03-15" @default.
• W3136540711 modified "2023-10-12" @default.
• W3136540711 title "Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study" @default.
• W3136540711 cites W1797768250 @default.
• W3136540711 cites W1799522345 @default.
• W3136540711 cites W1856405638 @default.
• W3136540711 cites W2016617267 @default.
• W3136540711 cites W2049438537 @default.
• W3136540711 cites W2051269651 @default.
• W3136540711 cites W2051745772 @default.
• W3136540711 cites W2092651879 @default.
• W3136540711 cites W2101996043 @default.
• W3136540711 cites W2110537835 @default.
• W3136540711 cites W2120058397 @default.
• W3136540711 cites W2125065061 @default.
• W3136540711 cites W2146316852 @default.
• W3136540711 cites W2148216588 @default.
• W3136540711 cites W2463483556 @default.
• W3136540711 cites W2507136820 @default.
• W3136540711 cites W2544680672 @default.
• W3136540711 cites W2587398798 @default.
• W3136540711 cites W2605785536 @default.
• W3136540711 cites W2606276381 @default.
• W3136540711 cites W2759604671 @default.
• W3136540711 cites W2788473137 @default.
• W3136540711 cites W2791839818 @default.
• W3136540711 cites W2800341633 @default.
• W3136540711 cites W2800483714 @default.
• W3136540711 cites W2808076807 @default.
• W3136540711 cites W2883718361 @default.
• W3136540711 cites W2893123471 @default.
• W3136540711 cites W2898214436 @default.
• W3136540711 cites W2900108004 @default.
• W3136540711 cites W2947167103 @default.
• W3136540711 cites W2966033892 @default.
• W3136540711 cites W2976321973 @default.
• W3136540711 cites W2982287013 @default.
• W3136540711 cites W2994205381 @default.
• W3136540711 cites W3015207295 @default.
• W3136540711 cites W3023583883 @default.
• W3136540711 cites W3036302070 @default.
• W3136540711 cites W3049529761 @default.
• W3136540711 cites W3090125069 @default.
• W3136540711 cites W3091646697 @default.
• W3136540711 cites W935432932 @default.
• W3136540711 doi "https://doi.org/10.3389/fmed.2021.637126" @default.
• W3136540711 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8005520" @default.
• W3136540711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33791326" @default.
• W3136540711 hasPublicationYear "2021" @default.
• W3136540711 type Work @default.
• W3136540711 sameAs 3136540711 @default.
• W3136540711 citedByCount "6" @default.
• W3136540711 countsByYear W31365407112021 @default.
• W3136540711 countsByYear W31365407112022 @default.
• W3136540711 countsByYear W31365407112023 @default.
• W3136540711 crossrefType "journal-article" @default.
• W3136540711 hasAuthorship W3136540711A5003240832 @default.
• W3136540711 hasAuthorship W3136540711A5010353663 @default.
• W3136540711 hasAuthorship W3136540711A5011302477 @default.
• W3136540711 hasAuthorship W3136540711A5018159361 @default.
• W3136540711 hasAuthorship W3136540711A5019709596 @default.
• W3136540711 hasAuthorship W3136540711A5081134218 @default.
• W3136540711 hasBestOaLocation W31365407111 @default.
• W3136540711 hasConcept C120665830 @default.
• W3136540711 hasConcept C121332964 @default.
• W3136540711 hasConcept C126322002 @default.
• W3136540711 hasConcept C159047783 @default.
• W3136540711 hasConcept C167135981 @default.
• W3136540711 hasConcept C17923572 @default.
• W3136540711 hasConcept C2522874641 @default.
• W3136540711 hasConcept C2775940106 @default.
• W3136540711 hasConcept C2776175608 @default.
• W3136540711 hasConcept C2777382497 @default.
• W3136540711 hasConcept C2777410769 @default.
• W3136540711 hasConcept C2777869810 @default.
• W3136540711 hasConcept C2779344132 @default.
• W3136540711 hasConcept C2780593183 @default.
• W3136540711 hasConcept C2781413609 @default.
• W3136540711 hasConcept C3013748606 @default.
• W3136540711 hasConcept C3020491458 @default.
• W3136540711 hasConcept C61511704 @default.
• W3136540711 hasConcept C71924100 @default.
• W3136540711 hasConcept C72563966 @default.
• W3136540711 hasConcept C88879693 @default.
• W3136540711 hasConcept C90924648 @default.
• W3136540711 hasConceptScore W3136540711C120665830 @default.
• W3136540711 hasConceptScore W3136540711C121332964 @default.
• W3136540711 hasConceptScore W3136540711C126322002 @default.
• W3136540711 hasConceptScore W3136540711C159047783 @default.
• W3136540711 hasConceptScore W3136540711C167135981 @default.
• W3136540711 hasConceptScore W3136540711C17923572 @default.
• W3136540711 hasConceptScore W3136540711C2522874641 @default.

• next